Invasive candidiasis: current clinical challenges and unmet needs in adult populations.

"Transparency declarations: A.S. has served as speaker and has participated in advisory boards for Pfizer, Merck Sharp & Dohme, Menarini, Shionogi, Gilead, Roche, Mundipharma and Angelini. P.M.H. has received honoraria for talks from Mundipharma, Pfizer, and Merck Sharp & Dohme; and has received grants from Pfizer. P.P.-A. has received honoraria for talks on behalf of Merck Sharp & Dohme, Lilly, ViiV Healthcare and Gilead Sciences. P.P.-A. has participated in advisory boards for Gilead Sciences. C.G.V. has served as speaker and has participated in advisory boards for Pfizer, Merck Sharp & Dohme, Menarini, Shionogi, Gilead Sciences, Roche and Janssen. D.C.G.B. and A.P. are employed by Symmetron Ltd and were commissioned by Mundipharma Research Limited to develop and write this article. PEV has received honoraria for talks from Mundipharma, F2G, Gilead Sciences and Pfizer and received research grants from F2G and Gilead Sciences. All payments were to the hospital. This article was co-developed and published based on all authors’ approval."

"Funding This article was sponsored by Mundipharma Research Limited."